Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Nischal, Ken
ROP3, NCT04634604: A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP	Terminated	3	16	Canada, US	Bevacizumab, Avastin, Laser	Jaeb Center for Health Research, Pediatric Eye Disease Investigator Group, National Eye Institute (NEI)	Retinopathy of Prematurity	08/23	08/23
ROP4, NCT04634578: Bevacizumab Treatment For Type 1 ROP	Recruiting	2	80	Canada, US	Bevacizumab, Avastin	Jaeb Center for Health Research, Pediatric Eye Disease Investigator Group, National Eye Institute (NEI)	Retinopathy of Prematurity	07/25	07/27
Rogers, David
ROP4, NCT04634578: Bevacizumab Treatment For Type 1 ROP	Recruiting	2	80	Canada, US	Bevacizumab, Avastin	Jaeb Center for Health Research, Pediatric Eye Disease Investigator Group, National Eye Institute (NEI)	Retinopathy of Prematurity	07/25	07/27
NCT05152914: Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2	Active, not recruiting	1/2	5	US	Cerliponase Alfa, Brineura	David L Rogers, MD	Neuronal Ceroid Lipofuscinosis Type 2	11/25	11/27